Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pharvaris N.V. (NQ: PHVS )

22.29 +1.25 (+5.94%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pharvaris N.V.

< Previous 1 2 3 4 5 Next >
Why PhenomeX Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) jumped 85.4% to $0.1267 after the company and Farm 7 Group announced a joint venture for Kenya Agricultural Cooperative Project. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2023
Via Benzinga
8 Analysts Have This to Say About Pharvaris
Via Benzinga
Analyst Expectations for Pharvaris's Future
Via Benzinga
Paysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones falling around 300 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit
From Pharvaris N.V.
Via GlobeNewswire
Why Shares of Pharvaris N.V. Are Up Tuesday
Promising news from the Food and Drug Administration spurred the healthcare stock's rise. 
Via The Motley Fool
5 Analysts Have This to Say About Pharvaris
Via Benzinga
What 4 Analyst Ratings Have To Say About Pharvaris
Via Benzinga
FDA Removes Clinical Hold Of Pharvaris' Deucrictibant For On-Demand Treatment Of HAE
Pharvaris NV (NASDAQ: PHVS) announced that the FDA lifted the clinical hold on the Investigational New Drug (IND) application for deucrictibant (PHA-121) for the on-demand  
Via Benzinga
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces $70 Million Private Placement Financing
From Pharvaris N.V.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning! 
Via InvestorPlace
Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Annual Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks Highlighted at the 2023 HAEi Regional Conference APAC
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Present in Upcoming March Investor Conferences
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks at AAAAI Annual Meeting
From Pharvaris N.V.
Via GlobeNewswire
Why Fulcrum Therapeutics Shares Are Trading Lower By Over 55%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) shares jumped 129.6% to $10.15. Jeffrey E. Kelter reported a 22.4% stake in a 13D filing on Thursday. 
Via Benzinga
Pharvaris to Present at SVB Securities Global Biopharma Conference
From Pharvaris N.V.
Via GlobeNewswire
Catalyst Pharmaceuticals, Xylem And Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones gaining over 300 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
CommVault Systems, Halozyme Therapeutics And Other Big Stocks Moving Lower On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining around 80 points on Wednesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Pharvaris Provides Regulatory, Clinical, and Corporate Updates
From Pharvaris N.V.
Via GlobeNewswire
EXCLUSIVE: Top 10 Searched Tickers On Benzinga Pro In December 2022: Where Do Tesla, Apple, AMC Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday's Mid-Day Session
Gainers Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal... 
Via Benzinga
Dow Tumbles 150 Points; Crude Oil Falls Sharply
U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 150 points on Wednesday. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.